Skip to main content

Table 2 Ferroptosis and cancer therapy

From: Induction and application of ferroptosis in cancer therapy

Therapy Treatment Combination drugs Mechanism Tumour type Refs
Chemotherapy Sorafenib siRNA Inhibit the MT-1G and the system xc- HCC, RCC, NSCLC, PDAC [34, 67, 134, 135]
Artemisinin Iron Increase the level of intracellular free iron PDAC, AML, HNSCC [122,123,124,125]
Cyst(e)inase FINs Deplete extracellular cystine PDAC, Prostate cancer,
Chronic lymphocytic leukemia
[109, 116]
Statins - Reduce selenoproteins (such as GPX4) and CoQ10 biosynthesis Breast Cancer [138]
Radiotherapy RT FINs Up-regulates ACSL4,
inhibit SLC7A11 or GPX4
Neuroblastoma, NSCLC, Fibrosarcoma, Melanoma, Breast Cancer,
Cervical cancer
Immunotherapy PD-L1 inhibitors FINs Releas IFNγ to reduce the uptake of cystine Fibrosarcoma [11]
TGF-β inhibitors and PD-1 antibodies FINs Generate an immunogenic microenvironment and produce H2O2, promoting the Fenton reaction Melanoma [146]
Nanomedicine Metal–Organic Frameworks (MOF) Release iron Mononuclear macrophage leukemia [148]
FePt-NP2 Iron nanoparticles and cisplatin Increase the sensitivity of cancer cells to cisplatin Ovarian cancer [117]
SRF@FeIIITA (SFT) Fe3+ and TA, nanocrystals of SRF, Inhibit GPX4 and generate ROS Fibrosarcoma [71]
Nano-delivery vehicle WithaferinA, IKE Improve solubility and biocompatibility, and increase accumulation Neuroblastoma, DLBCL [84, 99]
AMSNs Target cancer by ASS and release Mn ion to consume GSH HCC [149]
MON-p53 Providie unstable iron, and deliver p53 to cells Fibrosarcoma [150]
Ultra-small poly(ethylene glycol) coated silica nanoparticles Transport of extracellular iron into the cell NeuroblastomaHCC [151]
PDT FINs Produce ROS and consume O2 OTSCC, Breast Cancer, HCC [152,153,154,155,156,157]
produce ROS and consume O2
CRC, Breast Cancer [121, 158, 159]
  1. HCC hepatocellular carcinoma, RCC renal cell carcinoma, PDAC pancreatic ductal adenocarcinoma, HNSCC head and neck squamous cell carcinoma, NSCLC non- small- cell lung cancer, AML acute myeloid leukaemia, DLBCL diffuse large B cell lymphoma, GSH glutathione, TA tannic acid, SRF sorafenib, ASS arginine succinate synthase, PDT photodynamic therapy, PTT photothermal therapy